Clinical Trial

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and…

2 months ago

Cryoport Reports Third Quarter 2024 Financial Results

Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of…

2 months ago

Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth

ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

2 months ago

Avinger Reports Third Quarter 2024 Results

Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 /…

2 months ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe…

2 months ago

Cellev8 Nutrition Shareholder Update

WELLINGTON, FL / ACCESSWIRE / November 7, 2024 / Dear Valued Shareholders,I am thrilled to share with you some of…

2 months ago

Health Union Releases 2024 Findings of “In America” and “Patient Experience” Syndicated Healthcare Research, Offering Unmatched Patient Insights

With data from over 37,000 individuals across 50+ conditions, Health Union's 2024 syndicated healthcare research findings provide fresh perspectives on…

2 months ago

Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device

New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif., Nov. 7, 2024 /PRNewswire/ --…

2 months ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…

2 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by…

2 months ago